Tim Leest succeeds Dr Violeta Stoyanova-Beninska as a chair, following her completion of the maximum two three-year terms allowed for COMP chairs.
COMP is responsible for evaluating applications for orphan designation. This designation is for medicines to be developed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or very serious. COMP also advises and assists the European Commission on matters related to orphan medicines
Source/Attributions: This news post was originally posted at www.ema.europa.eu
